Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology (Baltimore, MD). 2015;61(1):191–199.
   PubMed Web of Science ®Google Scholar
• Mokdad AA, Hester CA, Singal AG, et al. Management of hepatocellular in the United States. Chin Clin Oncol. 2017;6(2):21.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (Baltimore, MD). 1999;29(1):62–67.
   PubMed Web of Science ®Google Scholar
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, MD). 2011;53(3):1020–1022.
   PubMed Web of Science ®Google Scholar
• Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–474.
   PubMed Web of Science ®Google Scholar
• Sherman M. Alphafetoprotein: an obituary. J Hepatol. 2001;34(4):603–605.
   PubMed Web of Science ®Google Scholar
• Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138(2):493–502.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology. 2009;137(1):26–29.
   PubMed Web of Science ®Google Scholar
• Sherman M. Serological surveillance for hepatocellular carcinoma: time to quit. J Hepatol. 2010;52(4):614–615.
   PubMed Web of Science ®Google Scholar
• Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47.
   PubMed Web of Science ®Google Scholar
• Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin Mol Hepatol. 2016;22(1):7–17.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, MD). 2018;67(1):358–380.
   PubMed Web of Science ®Google Scholar
• Joshi K, Mendler M, Gish R, et al. Hepatocellular carcinoma surveillance: a national survey of current practices in the USA. Dig Dis Sci. 2014;59(12):3073–3077.
   PubMed Web of Science ®Google Scholar
• Singal AG, Nehra M, Adams-Huet B, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108(3):425–432.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Said A, Ness R, et al. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol. 1999;94(8):2224–2229.
   PubMed Web of Science ®Google Scholar
• Van Kleek EJ, Schwartz JM, Rayhill SC, et al. Liver transplantation for hepatocellular carcinoma: a survey of practices. J Clin Gastroenterol. 2006;40(7):643–647.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Alsarraj A, Richardson P, et al. Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey. Dig Dis Sci. 2013;58(11):3117–3126.
   PubMed Web of Science ®Google Scholar
• van Meer S, de Man RA, Coenraad MJ, et al. Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands. J Hepatol. 2015;63(5):1156–1163.
   PubMed Web of Science ®Google Scholar
• Del Poggio P, Olmi S, Ciccarese F, et al. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12(11):1927–1933.e2.
   PubMed Web of Science ®Google Scholar
• Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(1):169–177.
   PubMed Web of Science ®Google Scholar
• Wong LL, Reyes RJ, Kwee SA, et al. Pitfalls in surveillance for hepatocellular carcinoma: how successful is it in the real world? Clin Mol Hepatol. 2017;23(3):239–248.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30(01):61–74.
   PubMed Web of Science ®Google Scholar
• Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21(5):793–799.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ. NASH: a global health problem. Hepatol Res. 2011;41(7):670–674.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273.e1.
   PubMed Web of Science ®Google Scholar
• Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–1718.e1.
   PubMed Web of Science ®Google Scholar
• Chang TS, Wu YC, Tung SY, et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am J Gastroenterol. 2015;110(6):836–844.
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL, Tse YK, et al. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology (Baltimore, MD). 2014;59(3):986–995.
   PubMed Web of Science ®Google Scholar
• Cho JY, Paik YH, Sohn W, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut. 2014;63(12):1943–1950.
   PubMed Web of Science ®Google Scholar
• Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34(4):570–575.
   PubMed Web of Science ®Google Scholar
• Chen TM, Huang PT, Tsai MH, et al. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol. 2007;22(5):669–675.
   PubMed Web of Science ®Google Scholar
• Giannini EG, Cucchetti A, Erroi V, et al. Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World J Gastroenterol. 2013;19(47):8808–8821.
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43(3):434–441.
   PubMed Web of Science ®Google Scholar
• Abdel-Razik A, Mousa N, Abdel-Aziz M, et al. Elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C virus genotype 4: not the end of the story. Eur J Gastroenterol Hepatol. 2016;28(3):313–322.
   PubMed Web of Science ®Google Scholar
• Kakisaka K, Kataoka K, Onodera M, et al. Alpha-fetoprotein: a biomarker for the recruitment of progenitor cells in the liver in patients with acute liver injury or failure. Hepatol Res. 2015;45(10):E12–E20.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014;23(1):144–153.
   PubMed Web of Science ®Google Scholar
• White DL, Richardson P, Tayoub N, et al. The updated model: an adjusted serum alpha-fetoprotein-based algorithm for hepatocellular carcinoma detection with hepatitis C virus-related cirrhosis. Gastroenterology. 2015;149(7):1986–1987.
   PubMed Web of Science ®Google Scholar
• Tayob N, Lok AS, Do KA, et al. Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm. Clin Gastroenterol Hepatol. 2016;14(3):469–475.e2.
   PubMed Web of Science ®Google Scholar